1. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
- Author
-
Giuseppe Romanelli, Maria Pia Sormani, Stefania Cossi, Ruggero Capra, Cristina Scarpazza, Flavia Mattioli, and Nicola De Rossi
- Subjects
Male ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Respiratory failure ,chemistry.chemical_compound ,0302 clinical medicine ,Receptors ,Monoclonal ,SARS-cov-2 ,Respiratory function ,Viral ,030212 general & internal medicine ,skin and connective tissue diseases ,Humanized ,Respiration ,Mortality rate ,Middle Aged ,Tocilizumab ,Respiratory Function Tests ,Retrospective study ,Outcome and Process Assessment, Health Care ,Italy ,Artificial ,Female ,Drug ,Coronavirus Infections ,Respiratory Insufficiency ,COVID-19 ,Pneumonia ,musculoskeletal diseases ,medicine.medical_specialty ,Respiratory rate ,Pneumonia, Viral ,Antibodies, Monoclonal, Humanized ,Aged ,Antiviral Agents ,Betacoronavirus ,Dose-Response Relationship, Drug ,Early Medical Intervention ,Humans ,Receptors, Interleukin-6 ,Respiration, Artificial ,Retrospective Studies ,Pandemics ,Outcome and Process Assessment ,Antibodies ,Article ,Dose-Response Relationship ,03 medical and health sciences ,Internal medicine ,Internal Medicine ,medicine ,Survival rate ,Mechanical ventilation ,Interleukin-6 ,business.industry ,medicine.disease ,respiratory tract diseases ,Health Care ,chemistry ,business - Abstract
Highlights • Pneumonia with respiratory failure represents the main cause of death in COVID-19. • Hyperinflammation plays an important role in COVID-19 lung damage. • Tocilizumab might be helpful to treat COVID-19 related pneumonia. • 8% vs 57% of deaths were observed in patients treated or not treated with tocilizumab. • Early administration of tocilizumab drastically reduced mortality rate in our sample. • Tocilizumab might prevent excessive lung damage and death in patients with COVID-19., Background Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients’ mortality. Methods 85 consecutive patients admitted to the Montichiari Hospital (Italy) with COVID-19 related pneumonia and respiratory failure, not needing mechanical ventilation, were included if satisfying at least one among: respiratory rate ≥ 30 breaths/min, peripheral capillary oxygen saturation ≤ 93% or PaO2/FiO2
- Published
- 2020